Overview

This trial is active, not recruiting.

Conditions papillomavirus infections, health behavior, attitude of health personnel, human papilloma virus, male
Treatment survey
Sponsor Louisiana State University Health Sciences Center Shreveport
Start date July 2016
End date August 2016
Trial size 400 participants
Trial identifier NCT02897232, STUDY00000618

Summary

This is a minimal risk, anonymous, convenience sample, social behavioral study using qualitative descriptive survey methods. It is to ascertain community member, physician, resident and medical student perspectives regarding Human Papillomavirus (HPV) infection, associated diseases and to identify barriers which prevent these groups from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection.

The research is focused on these questions:

Do community members understand the ease of transmission of the HPV virus in males 9-26? Do community members, physicians, residents and medical students have knowledge of the associated diseases that may occur with the HPV virus infection in males age 9-26? Do community members, physicians, residents and medical students know the ages in which males should receive the HPV vaccine three-shot series? What barriers prevent community members and physicians, residents and medical students from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection?

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model ecologic or community
Time perspective retrospective
Arm
Community members coming into the University Health Shreveport Ambulatory Care Facility.
survey
Clinical Faculty and community will be given a survey to define issues preventing HPV Vaccination
Physicians affiliated with LSU Health Shreveport School of Medicine
survey
Clinical Faculty and community will be given a survey to define issues preventing HPV Vaccination

Primary Outcomes

Measure
Barriers to HPV Vaccination
time frame: 60 days

Secondary Outcomes

Measure
Knowledge pertaining to ease of Human Papillomavirus transmission.
time frame: 60 days
Knowledge of Associated HPV diseases
time frame: 60 days
Knowledge of age in which males should be vaccinated against HPV.
time frame: 60 days

Eligibility Criteria

Male or female participants at least 18 years old.

Community Study Inclusion All visitors to the Pediatric or Internal Medicine University Health Shreveport Clinics who are willing to complete a survey asking them about their knowledge and attitudes towards HPV vaccination in males age 9-26. Participants do not have to have a child with an appointment at the clinic or have an individual appointment. Since the study is using a convenience sample, surveying anyone present who matches the above Inclusion criteria is appropriate. Community Study Exclusion Those do not wish to participate in the study and those who English is not their first language Clinical Faculty, Resident, and Medical Student Study Inclusion All Louisiana State University Shreveport Health Clinical Faculty, Resident, and Medical Student Inclusion who wish to complete the online survey asking them about their knowledge of HPV, knowledge of who should be vaccinated and what barriers exist to promoting the HPV three-shot vaccination in males age 9-26. Clinical Faculty, Resident, and Medical Student Study Exclusion Any LSU Health Shreveport Clinical Faculty, Resident, and Medical Student which declines to take the survey or do not attempt to complete it.

Additional Information

Official title Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination
Principal investigator Julia M Esparza, MLS
Description This is a minimal risk, anonymous, convenience sample, social behavioral study using qualitative descriptive survey methods. It is to ascertain community member, physician, resident and medical student perspectives regarding Human Papillomavirus (HPV) infection, associated diseases and to identify barriers which prevent these groups from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection. The research is focused on these questions: Do community members understand the ease of transmission of the HPV virus in males 9-26? Do community members, physicians, residents and medical students have knowledge of the associated diseases that may occur with the HPV virus infection in males age 9-26? Do community members, physicians, residents and medical students know the ages in which males should receive the HPV vaccine three-shot series? What barriers prevent community members and physicians, residents and medical students from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection?
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Louisiana State University Health Sciences Center Shreveport.